Back to top
more

Puma Biotechnology (PBYI)

(Delayed Data from NSDQ)

$2.95 USD

2.95
429,641

+0.10 (3.51%)

Updated Nov 1, 2024 04:00 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.10%
2Buy17.80%
3Hold9.50%
4Sell2.70%
5Strong Sell2.70%
S&P50011.20%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

4-Sell of 5       4  

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

A Value C Growth B Momentum A VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 36% (89 out of 250)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

IGM Bio (IGMS) Stock Rallies 142% in 3 Months: Here's Why

by Zacks Equity Research

IGM Bio (IGMS) stock surges 142% in the past three months on strategic reprioritization efforts to focus its resources on the development of pipeline candidates for cancer and autoimmune indications.

Adicet (ACET) Stock Rallies 130% in a Month: Here's Why

by Zacks Equity Research

Adicet (ACET) skyrockets 130% on a corporate update provided by the company discussing strategic priorities for 2024.

Solid Biosciences (SLDB) Rises 271% in 3 Months: Here's Why

by Zacks Equity Research

The FDA's recent clearance of Solid Biosciences' (SLDB) investigational new drug application on SGT-003 for treating Duchenne muscular dystrophy pushes the stock higher.

Inovio Pharma (INO) Stock Rallies 134% in a Month: Here's Why

by Zacks Equity Research

Inovio Pharma (INO) surges 134% in a month, mainly due to its plans to submit a regulatory application seeking approval of its lead candidate, INO-3107, in the second half of 2024 to treat RRP.

Amicus (FOLD) Stock Rises More Than 25% in 3 Months: Here's Why

by Zacks Equity Research

Sales of Amicus' (FOLD) lead drug, Galafold, are rising consistently. Also, the recent approval of the Pompe disease drug combination, Pombiliti + Opfolda, is a positive.

Amarin (AMRN) Stock Rises on Stellar Q4 Preliminary Results

by Zacks Equity Research

Amarin (AMRN) issues encouraging preliminary results for the fourth quarter and full-year 2023. The company also plans to initiate a share repurchase program of up to $50 million. Stock gains.

Mirati (MRTX) Gets EU Nod for Krazati in KRAS-Mutated NSCLC

by Zacks Equity Research

Mirati's (MRTX) Krazati gets the European Commission's conditional marketing approval for treating adult patients with KRASG12C-mutated advanced non-small cell lung cancer.

Xeris (XERS) Up on Licensing Deal With Amgen to Develop Tepezza

by Zacks Equity Research

Xeris (XERS) gains 16% after signing a licensing deal with Amgen, which allows the latter to utilize the XeriJect technology to develop a subcutaneous formulation of teprotumumab in Thyroid Eye Disease.

Here's Why You Should Invest in Ocuphire Pharma (OCUP) Now

by Zacks Equity Research

Here, we discuss some reasons why buying Ocuphire Pharma (OCUP) stock now may turn out to be a prudent move.

SELLAS (SLS) Rises on FDA Fast Track Tag to Leukemia Candidate

by Zacks Equity Research

The FDA bestows a Fast Track Designation to SELLAS' (SLS) pipeline candidate, SLS009, for the treatment of relapsed/refractory acute myeloid leukemia. Stock gains.

Atea Pharma (AVIR) Gains on Upbeat Initial Data From HCV Study

by Zacks Equity Research

Atea Pharma (AVIR) gains 11% after reporting positive initial results from the first 52 patients in the lead-in cohort of the mid-stage study evaluating its bemnifosbuvir/RZR combo to treat HCV.

GSK to Buy Private Biotech, Strengthen Respiratory Pipeline

by Zacks Equity Research

GSK's proposed acquisition of Aiolos is set to add the latter's long-acting anti-TSLP monoclonal antibody, AIO-001, to GSK's broad portfolio of respiratory products.

Novo Nordisk's (NVO) Phase III Diabetes Study Meets Primary Goal

by Zacks Equity Research

Novo Nordisk (NVO) reports positive top-line data from one of its late-stage studies under the COMBINE program evaluating once-weekly IcoSema in type II diabetes patients.

Sarepta (SRPT) Rises on Solid Q4 and 2023 Preliminary Results

by Zacks Equity Research

Sarepta (SRPT) issues encouraging preliminary results for the fourth quarter and full-year 2023. Shares of the company rise.

Corcept (CORT) Stock Rises on Upbeat Revenue Guidance for 2024

by Zacks Equity Research

Corcept (CORT) issues encouraging preliminary results for the fourth quarter and full-year 2023. Shares of the company rise on robust 2024 revenue guidance.

Apellis (APLS) Up on Strong Q4 Preliminary Syfovre U.S. Revenues

by Zacks Equity Research

Apellis (APLS) reports strong preliminary net product revenues in the United States for the fourth quarter of 2023, driven by robust Syfovre sales. The stock gains 15%.

Alnylam (ALNY) Posts Preliminary Q4 & Full-Year '23 Revenues

by Zacks Equity Research

Alnylam (ALNY) reports preliminary full-year and fourth-quarter 2023 net product revenues.

Ultragenyx's (RARE) Preliminary 2023 Revenues Disappoint

by Zacks Equity Research

Ultragenyx (RARE) reports preliminary full-year 2023 revenues, along with business updates, and shares 2024 revenue guidance.

PBYI vs. VRTX: Which Stock Is the Better Value Option?

by Zacks Equity Research

PBYI vs. VRTX: Which Stock Is the Better Value Option?

Amicus (FOLD) Issues Preliminary Revenue Results for FY23

by Zacks Equity Research

Amicus (FOLD) posts preliminary results for full-year 2023. The company also provides a strategic outlook for 2024.

Axsome (AXSM) Stock Rises on Stellar Q4 Preliminary Results

by Zacks Equity Research

Axsome (AXSM) issues encouraging preliminary results for the fourth quarter and full-year 2023. The company also provides regulatory updates on its pipeline candidates. Shares rise.

Innate Pharma (IPHA) Gains as FDA Lifts Hold on Lymphoma Study

by Zacks Equity Research

Innate Pharma (IPHA) stock moves up in the pre-market hours as the FDA lifts the partial clinical hold placed on a study evaluating lacutamab for Sezary syndrome.

Collegium (COLL) Shares Rise on Financial Outlook for 2024

by Zacks Equity Research

Collegium (COLL) reports financial guidance for full-year 2024 and business updates. Shares of the company rise on the same.

Assertio (ASRT) Shares Fall as Dan Peisert Steps Down as CEO

by Zacks Equity Research

Assertio (ASRT) appoints Heather Mason as its interim CEO as its current CEO, Dan Peisert, steps down from his role. Shares of the company fall on the same.

Here's Why You Should Invest in Adverum (ADVM) Stock Now

by Zacks Equity Research

Here, we discuss some reasons why buying Adverum Biotechnologies (AQST) stock now may turn out to be a prudent move.